Director SHERMAN JEFFREY W purchased 5,000 shares of LRMR at $5.00 on 2026-02-27; cluster pattern with 3 other insiders buying in past 14 days.
Director Sherman Jeffrey W acquired 5,000 shares at $5.00, establishing an initial position in Larimar Therapeutics at a price now 4.4% above the transaction level ($5.23 current). The transaction is part of a cluster pattern with 3 other insiders also purchasing within the past 14 days, indicating coordinated board-level activity. The company is unprofitable with a net loss of $-47.7M in the latest full year and zero revenue in the latest quarter, characteristic of a clinical-stage or early-stage biotech. The stock has appreciated 67.6% over the past 90 days and 47.7% over the past 30 days, placing it near its 52-week high of $5.95, yet the cluster buying continues despite this elevated valuation context.